ClinicalTrials.gg
RecruitingNCT06339190NAVAIDDUpdated Oct 8, 2026

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis

An observational study in Neurodegenerative Diseases and Dementia, sponsored by Monash University. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Monash University · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.
Updated Oct 8, 2026Primary completion movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Neurodegenerative Diseases with a site in Australia — 6 open to participants now, 12 under way, 2 of them phase 3. Neurodegenerative Diseases · Australia.

Started
2021
with 2 others
Observational
2 of 31
2 open now
Primary completion
2027-03
later than 4 of 11 live
Registered
23rd of 31
by date

Among the 31 studies in Neurodegenerative Diseases with a site in Australia, this one is one of 3 that started in 2021, is one of 2 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 23rd registered.

Neurodegenerative Diseases

436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.

Browse Neurodegenerative Diseases studies →

Open to participants now

6 of the 31 studies in Neurodegenerative Diseases with a site in Australia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Neurodegenerative Diseases with a site in Australia, or all of them as a file.
02

Study summary

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.

Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.

Individuals at risk of a genetic dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.

Read the detailed description

Problem: There is no "gold-standard test" to detect all forms of dementia. People can present with subtle changes that are missed on standard cognitive screening tests, which are not designed for people whose first language is not English or from diverse cultural and educational backgrounds. State-of-the art brain imaging is only available to Australians living in large urban centres, further entrenching health care inequities. The lack of validated diagnostic tests and pathways causes diagnostic delays, increases patient and caregiver stress. Therapies are on the horizon for many forms of dementia - not only Alzheimer's disease - meaning that the lack of identification of simple dementia diagnostic biomarkers represents a critical knowledge gap.

Mission: New technologies now allow us to test abnormal brain protein levels in a routine peripheral blood test, record a voice sample to analyse its acoustics and reveal brain disease, and perform "mail-out" genetic tests using a simple saliva sample. The levels of a brain derived blood protein, neurofilament light chain (NfL), will be estimated and natural language processing and acoustic analysis will be measured in all patients presenting with cognitive complaints to a single healthcare network servicing 1 million ethnically and culturally diverse Australians. Researchers will investigate the utility of early genetic testing for those at high risk of a genetic cause for their disease. They will use these data to develop diagnostic pathways, leveraging existing collaborations to develop future screening programs. Early to mid-career researchers will be supported to translate new technologies into clinical practice in the shortest practicable time-frame.

Significance: Accessible and cost effective tests will inform new pathways to dementia diagnosis. This will transform the dementia landscape, shortening time to diagnosis, increasing diagnostic certainty, and allowing more Australians access to appropriate care, education, and future therapies.

03

Conditions studied

  • Neurodegenerative Diseases
  • Dementia

Keywords

  • Alzheimer's disease
  • Dementia
  • Neurofilament light chain
  • Speech
  • Neurodegeneration
  • Biomarker
  • Health care disparity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study cohort will include any individual of all ages, ethnicities, identities and genders. This is to ensure that the findings are generalisable to other national healthcare networks and to provide maximum information on the utility of using blood-biomarker estimation in real-world clinical settings

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients presenting to Eastern Health services with a cognitive complaint or potential neurodegenerative disorder

Exclusion criteria

Exclusion Criteria:

  • Prognosis \<12 months
  • No cognitive complaint
  • Patients not involved within the single healthcare network
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testVenepuncture

    A single blood draw at the time of presentation to clinic or whilst an inpatient.

06

What researchers measure

Primary outcomes

  1. Baseline NfL level

    Plasma Nfl (pg/ml), estimated using Quanterix SIMOA HD-X

    Time frame: Day 0

Secondary outcomes

  1. Change in speech processing

    Staff and/or self administered using Redenlab software and analysed by speech pathologist for acoustic measures of timing (e.g., pause length (seconds) in reading and monologue tasks), vocal control (e.g., fundamental frequency (hertz) and loudness variation (decibel) from vowel and monologue), and vocal quality (e.g., dysphonia measures derived from sustained vowel).

    Time frame: Day 0 and 12-months

  2. Change in language processing

    Recorded by a member of the research team using Redenlab software and assessed by a speech therapist using Natural Language Processing techniques.

    Time frame: Day 0 and at 12-months

  3. Change in Direct Magnitude Estimation

    Perceptual rating of speech using Redenlab software; measuring intelligibility (i.e ability to be understood) and naturalness (deviation from healthy norm) of speech. Assessed by a speech therapist on a scale from 0 to 100; 0 indicates none of the speech is intelligible/natural, 100 indicates all the speech is intelligible/natural.

    Time frame: Day 0 and at 12-months

Other outcomes

  1. Modified Rankin Scale

    Functional screen; assessed by member of the research team based on clinical notes. Assessed as change from baseline. Scores ranging from 0-5, with higher scores indicating greater disability.

    Time frame: Day 0 and at 12-months

  2. Montreal Cognitive Assessment score

    Cognitive screen; staff administered via telephone. Scores include overall MoCA score (0-22) and Memory Index Score (0-15), greater scores indicate greater cognition.

    Time frame: At 12-months

  3. Hospital Anxiety and Depression Scale score

    Mood screen; staff administered via telephone. Scores include a total depression score (0-21) and total anxiety score (0-21); grouped according to normal (0-7), Borderline abnormal (8-10) and Abnormal (11-21).

    Time frame: At 12-months

  4. Clinical Global Impression score

    Global rating of improvement/change; staff administered via telephone. Scored on a 7 point scale, scores closer to 0 indicative of greater improvement and scores closer to 7 representing much worse).

    Time frame: At 12-months

  5. WHO Disability Assessment 12-item telephone interview score

    Functional screen, staff administered via telephone. Scored as an overall percentage (%) disability, higher scores indicating less function.

    Time frame: At 12-months

  6. WHO Disability Assessment 36-item self report score

    Functional screen, self administered. Scored as an overall percentage (%) disability, higher scores indicating less function.

    Time frame: At 12-months

  7. DNA sample for testing known pathogenic dementia mutations

    Self-administered saliva sample; Testing using Invitae Fronto-temporal dementia and AD panel: C9orf72, CHCHD10, CHMP2B, DCTN1, FUS, GRN, HNRNPA2B1, MAPT, SQSTM1, TARDBP, TBK1, TREM2, UBQLN2, VCP, APP, PSEN1 and PSEN2

    Time frame: Anytime over the study duration

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Ivanic S, Vogel AP, Chatterjee P, Baird J, Darby D, Werden E, Gao L, Darzins P, Patel SK, Burke I, Morris T, Churilov L, Bice J, Mielke MM, Brodtmann A. Neurofilament light chain and voice acoustics in dementia diagnosis (NAVAIDD): Protocol for a cohort study assessing the real-world diagnostic utility of blood and digital biomarkers in clinical settings. J Alzheimers Dis Rep. 2025 Dec 15;9:25424823251395325. doi: 10.1177/25424823251395325. eCollection 2025 Jan-Dec. PubMed 41409494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Mar 2027, 67 months after the start.

Of 82 observational studies under Neurodegenerative Diseases, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 216. This study's planned 67 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Mar 2027, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Apr 1, 2024
StartActual
Aug 1, 2021
Primary completionEst.
Mar 2027was Dec 2025
CompletionEst.
Dec 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Mar 2027
Oct 8, 2026
Eligibility
Minimum age none→18 Years
Oct 8, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41409494 ↗
Oct 8, 2026
Secondary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameother outcomeDNA sample for testing known pathogenic dementia mutationsAnytime before 12-months → Anytime over the study duration
  • Descriptionother outcomeDNA sample for testing known pathogenic dementia mutations: how it is measured was reworded
Oct 8, 2026
Sponsor
Collaborators removed: Invitae Corporation
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41409494 ↗
    Primary completion Dec 2025→Mar 2027
    Eligibility Minimum age none→18 Years
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameother outcomeDNA sample for testing known pathogenic dementia mutationsAnytime before 12-months → Anytime over the study duration
    • Descriptionother outcomeDNA sample for testing known pathogenic dementia mutations: how it is measured was reworded
    Sponsor Collaborators removed: Invitae Corporation
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06339190
Lead sponsor
Monash University
Collaborators
Eastern Health, University of Melbourne, Wake Forest University, Deakin University, The Florey Institute of Neuroscience and Mental Health, Redenlab
Responsible party
Amy Brodtmann (Professor, Monash University) — Principal investigator
First posted
Apr 1, 2024
Start date
Aug 1, 2021
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
Contact
amy.brodtmann@monash.edu
03 9094 9540
Svetlana Ivanic, BSc(Hons)
Contact
svetlana.ivanic@monash.edu
Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
principal investigator · Monash University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion